DiscoverMedical News PodcastICML 2025: Fixed-Duration and MRD-Guided Regimens in CLL
ICML 2025: Fixed-Duration and MRD-Guided Regimens in CLL

ICML 2025: Fixed-Duration and MRD-Guided Regimens in CLL

Update: 2025-09-29
Share

Description

Drs. Fahkri and Seshadri discuss recent studies on novel fixed-duration combinations and MRD-guided regimens for CLL. The Sequoia RMD study showed high efficacy with zanubrutinib and venetoclax, achieving a 99% response rate. Similarly, a phase 1 study with sornotoclax and zanubrutinib showed a 96% response rate. The UK FLAIR study demonstrated superior PFS and overall survival with ibrutinib plus venetoclax. The CLL18 trial evaluates MRD-guided vs. fixed-duration treatments with venetoclax and obinutuzumab or pirtobrutinib. Future CLL therapies may increasingly rely on MRD-guided approaches.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

ICML 2025: Fixed-Duration and MRD-Guided Regimens in CLL

ICML 2025: Fixed-Duration and MRD-Guided Regimens in CLL

PeerDirect Publishing